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Tokushima Research Institute, Otsuka Pharmaceutical Co., Ltd., Kawauchi-cho, Tokushima 771-01, Japan (Received for publication January 23, 1988) Large numbers of antibiotics have been discovered in the past 40 years and manymethods have been employed for discovery of novel antibiotics. Oneof them is the use of mutants that are highly sensitive to antibiotics. Recently /2-lactam antibiotic-hypersensitive mutants of Escherichia colil) and Pseudomonas aemginosa2) and an aminoglycoside-hypersensitive mutant of Klebsiella pneumoniaez) have been used in screening for new antibiotics. D-Cycloserine (DCS) has a broad antibacterial spectrum0 and acts on alanine racemase (EC 5. 1.1.1) and D-alanine: D-alanine ligase (EC 6.3.2.4), which are involved in synthesis of the peptidoglycan layer of the cell wall in bacteria5 »-6).
The antibiotics MK641/MK642r>8) and alaphosphin9) also have a similar mechanism of action.
Good synergy in bactericidal activity was demonstrated in the combinations between these antibiotics and /3-lactam antibiotics10). Therefore, DCS-type antibiotics are expected to be useful for clinical purposes, especially against -lactam resistant bacteria. It is anticipated that a DCS-sensitive mutant should be useful in detecting minor and novel DCS-type antibiotics produced in fermentation broths. Based on this concept, we obtained a very sensitive and highly specific mutant to DCS derived from Staphylococcus aureus Newman.
In this paper we report the isolation and characterization of the DCS hypersensitive mutant C-33, and its use in screening for antibiotics.
Induction and isolation of mutants were achieved by treating S. aureus Newman cells with 1 00 jug/ml of Ar-methyl-N' -nitro-N-nitrosoguanidine in 0. C-33 is not a ts-mutant. The MICof DCSagainst the mutant C-33 was 6 ng/ml, indicating that it was 8,000-fold moresensitive than the parent strain (MIC 50 jug/mi) to DCS. The inhibitory zones of DCS and other antibiotics against the C-33 and parent strains were determined by a conventional paperdisc method using NAmedium at 37°C ( Table 1) . The mutant C-33 showed specific sensitivity to DCSand was sensitive to 0.016^g/ml of DCS, while the parent strain showed no inhibitory zone even at 1 /^g/ml. The C-33 and parent cells were equally sensitive to all other antibiotics and agents tested except Triton X-100. To determine whether the antibiotics selected in the primary screen test by paper-disc assay wereinhibitors of cell wall synthesis, the rates of incorporation of radioactive precursors into the acid-insoluble macromolecular fraction in S. aureus C-33 at various concentrations of DCS were measured as described previously11} (Table   2 ). The syntheses of DNA,RNAand protein, assayed by measuring the incorporation of [3H]-thymidine,
[3H]uridine and [3H]leucine, respectively, were scarcely affected by incubation for 30 minutes with DCS, even at a concentration of 1 jug/ml which induced a relatively large inhibitory zone. However at the low concentration of 0.01 ywg/ml, DCS prevented the incorporation of iV-[14C]acetylglucosamme, a precursor of cell walls. Antibiotics other than cell wall inhibitors had no effect on the incorporation of JV-[14C]acetylglucosamine in either S. aureus C-33 or S. aureus Newman(data not shown). Triton X-100, to which the mutant C-33 was more sensitive than the parent strain, also did not affect the incorporation of JV-[14C]-acetylglucosamine into C-33. These results showed that assay of incorporation of this radioactive precursor could also be used in the second test to detect inhibitors of cell wall synthesis.
The rates of incorporation of several radioactive precursors in the mutant C-33 and the parent strain were compared (Fig. 1) . Growing TA-243 produced by Streptomyces griseofuscus OFR1388, a new antibiotic discovered by this screening procedure, is a novel inhibitor of cell wall synthesis. TA-243 was actively transported into bacterial cells by peptide transport system and was subsequently hydrolyzed by intracellular aminopeptidases to yield aminooxysuccinicacid. Its primary intracellular target site was alanine racemase (manuscript in preparation).
The strain C-33 is the first example of DCShypersensitive mutants. The above results indicate that it is a useful tool in screening work for new cell wall inhibitors. S-207~S-217, 1977 2) Kitano, K.; K. Nara & Y. Nakao: Screening 
